Serono entered into an exclusive license agreement with Nautilus Biotech’s to develop human growth hormone and an option to license the exclusive worldwide rights to improved variants of the protein. The deal could be worth up to €19 M (US$24.6 M) to Serono if specific milestones and sales targets are met.